Novartis Abogen Deal: $7.8 Billion mRNA Autoimmune License
Novartis Abogen deal: Abogen gets $575 million upfront and up to $7.2 billion in milestones for ABO2203, an mRNA T-cell engager for autoimmune disease.
Novartis Abogen deal: Abogen gets $575 million upfront and up to $7.2 billion in milestones for ABO2203, an mRNA T-cell engager for autoimmune disease.